

1 **A cost analysis comparing Seasonal Malaria**

2 **Chemoprevention with and without Vitamin A**

3 **Supplementation among under-5 children in Nigeria**

4 Olusola Oresanya^{1*}, Olujide Arije², Jesujuwonlo Fadipe¹, Kunle Rotimi¹, Abimbola Phillips³, Kolawole Maxwell⁴,
5 Emmanuel Shekarau⁵, Nneka Onwu⁶, and Eva S. Bazant⁷

6 ¹Technical, Malaria Consortium, Maitama, Abuja, Nigeria

7 ²Institute of Public Health, Obafemi Awolowo University, Ile-ife, Osun, Nigeria

8 ³Technical, Former Malaria Consortium, Maitama, Abuja, Nigeria

9 ⁴Managment, Malaria Consortium, Maitama, Abuja, Nigeria

10 ⁵Case management, National Malaria Elimination Programme, Abuja, Nigeria

11 ⁵Community Services, National Primary Health Care Development Agency, Abuja, Nigeria

12 ⁶Malaria Consortium, Kampala, Uganda

13 ⁷The Task Force for Global Health, Health Campaign Effectiveness Coalition, Decatur, Georgia, USA

14 * Corresponding author

15 Email: o.oresanya@malariaconsortium.org

16

17 **Abstract**

18 **Background:** Child mortality in Nigeria, significantly affected by malaria and malnutrition, remains a public
19 health concern in the country. Seasonal Malaria Chemoprevention (SMC) and Vitamin A supplementation (VAS)
20 are effective interventions that can be delivered through integrated health campaigns to reduce this mortality. This
21 study assesses the cost implications of integrating these two interventions among under-5 children in Northeast
22 Nigeria.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Methods:** A cost analysis compared standalone SMC (Cycle 1 in July 2021) with SMC-VAS integrated
24 campaign (Cycle 4 in October 2023) in two Local Government Areas (LGAs) in Bauchi State. The number of children
25 reached by the SMC-only campaign was 168,820 and for the SMC+Vit A campaign, the number was 170,681. Data
26 collection utilized a mixed-methods approach, drawing from primary and secondary sources, including
27 programmatic, financial, and coverage records. Costs were categorized into distribution, Sulphadoxine-
28 Pyrimethamine plus Amodiaquine (SPAQ) for SMC, Vitamin A, training, supplies, meetings, labor, supervision, and
29 social mobilization costs. Sensitivity analyses evaluated the effect of a 10% fluctuation in the costs of distribution,
30 labor, SPAQ, and supplies on the cost per child.

31 **Results:** The total cost for the SMC standalone campaign was US\$158,934, and the SMC-VAS integration was
32 US\$186,426. Distribution and drug costs were the largest contributors in the integrated and SMC-only campaign.
33 The SMC-only cost per child was \$0.94 and \$1.18 when eligible children received both SMC and VAS. The
34 integration of VAS into the SMC campaign cycle incurred an additional US\$27,492 over Cycle 1 cost (US\$186,426
35 - US\$158,934). Fluctuations in distribution costs were the most influential component of the cost per child.

36 **Conclusion:** Integrating VAS with SMC campaigns increases the cost by US\$0.24 per child, a modest
37 increment considering the potential health benefits. The results support the feasibility of this integration, in terms of
38 cost, to combat child mortality from malaria and malnutrition in Nigeria. Further research is recommended to explore
39 the cost-effectiveness of this integrated distribution model.

40 **Keywords:** Malaria, Seasonal Malaria Chemoprevention, Vitamin A, Supplementation, Integration

41 **Background**

42 In spite of documented global gains in child survival, one in every thirteen children in sub-Saharan Africa still face
43 huge health risks, especially mortality before their fifth birthday[1] . The leading causes of morbidity and mortality
44 among under-five children are infectious diseases (malaria) and malnutrition with Nigeria being the third largest
45 contributor to under-five mortality[1,2] . Nutrition-related factors heighten the risk of all cause childhood
46 mortality[1,3].

47 Central to the effort to combat malnutrition among under-five children is Vitamin A supplementation (VAS) as one
48 of the key strategies recommended[4]. It has been linked to significant reductions in morbidity and mortality among

49 children aged 6 to 59 months across various regions including Africa Asia and Latin America [5]. VAS is cost
50 effective in addressing global public health challenges among children[6,7]. However, VAS coverage in Nigeria
51 stands at 45.3%, below the World Health Organization's (WHO) recommended coverage of 80%[8], with children in
52 northern Nigeria nearly three times less likely to access VAS compared to their counterparts in the South[8].
53 Moreover, distributing Vitamin A supplements through health facilities often results in unequal access due to several
54 barriers including socio-cultural and economic factors[8,9].

55 Some countries with low VAS coverage have adopted strategies targeting the distribution of micronutrients, including
56 VAS, through established, culturally acceptable channels like community-based distribution[10,11]. Seasonal
57 malaria chemoprevention (SMC) can provide a ready platform for VAS delivery to enhance coverage and access.
58 This malaria prevention intervention delivers full courses of antimalarials to children living in areas with seasonal
59 transmission of malaria through a door-to-door campaign approach, A feasibility pilot study in northwest Nigeria
60 which integrated SMC and VAS in 2019 offered preliminary evidence of improved VAS coverage[12]. However,
61 evidence gaps, including feasibility of implementation in different contexts, equity, cost, efficiency, and safety of
62 integration, remain to be addressed before adopting this approach as a strategy. In response to the need to provide
63 additional evidence for policy decision-making on full-scale integration of VAS with SMC campaigns in Nigeria, a
64 comparative cost analysis of a standalone SMC campaign (cycle 1) and an integrated campaign of SMC plus VAS
65 (cycle 4) was carried out.

66 The objective was to robustly compare the cost per eligible child between a stand-alone SMC campaign cycle and an
67 integrated SMC-VAS campaign cycle, providing valuable insights for estimating the expenses of future interventions
68 aiming to implement VAS, especially in conjunction with SMC.

69 **Methods**

70 **Study setting**

71 This study was carried out in Bauchi State, where children face considerable health risks. According to the 2018
72 Nigeria's Nutrition Health Standardized Monitoring and Assessment of Relief and Transition (SMART) Survey
73 report, Bauchi state has the 7th highest rate of malnutrition in Nigeria (25.5%) significantly higher than the national
74 average of 19.9%, ranks 3rd highest with 8.2% prevalence of severe malnutrition, and 2nd highest in North East with
75 stunting prevalence of 45.6% (compared to the national average of 32%) among children 0-59 months[5]. Bauchi
76 State was selected for the integrated campaign because of its low (29%) coverage of Vitamin A among 6-59 months
77 in 2018 according to the National Nutrition and Health Survey, a level lower than the national average of 41% [14].

78 Giade LGA is rural with 51,839 children under-5 years old in a total population of 259,192 (2021 projected
79 population) while Katagum is urban with 97,743 children under five years in a population of 488,715 (2021 projected
80 population) [14].

81 **SMC-VAS Integrated Intervention**

82 SMC entails monthly administration of a three-day treatment regimen comprising sulfadoxine-pyrimethamine (SP)
83 and amodiaquine (AQ), collectively referred to as SPAQ, to children aged 3–59 months. Typically, community
84 distributors administer the first dose of SPAQ in person, followed by two additional doses of AQ provided by
85 caregivers on the second and third days following the initial dose. Each complete SPAQ course confers protection
86 for approximately one month. Each treatment sequence, along with its protective duration, is termed an ‘SMC cycle’
87 and four to five cycles are typically provided to cover the malaria transmission season. Figure 1 (Typical design of
88 SMC drug distribution campaign) below shows the typical timeline for one cycle of a drug distribution campaign.

89 Malaria Consortium supported the state malaria programme to implement a four-cycle SMC delivery in ten Local
90 Government Areas (LGAs) in Bauchi State in 2021. SMC-VAS integration implementation research was conducted
91 in two of the ten LGAs, Giade and Katagum, between June and November 2021 because of their location and stable
92 security status in a region that has reported various security threats in the past few years[13].

93 Inclusion criterion for receiving SPAQ was children 3 – 59 months of age, and exclusion criteria were: very sick
94 child, child with fever (who was referred to the nearest health facility for a malaria test), child with known allergy to
95 Sulfadoxine pyrimethamine (SP) or Amodiaquine (AQ), or who has taken SP or cotrimoxazole in the last 4 weeks.
96 Inclusion criterion for receiving Vitamin A was children between 6 – 59 months of age, while children with severe
97 respiratory infection or difficulty with breathing and children who have taken Vitamin A within the past four months
98 were excluded.

99 SMC drugs and vitamin A were administered to eligible children using community drug distributors (CDD)¹ who are
100 volunteer members of the communities recruited to distribute SPAQs within their communities and they carry out
101 the distribution through a door-to-door delivery strategy during SMC campaigns. Cycles 1-3 had standalone SMC
102 administration over four days each between June and September 2021, while the integrated delivery of SMC and
103 Vitamin A was implemented during Cycle 4 over five days in October 2021 in the two selected LGAs. The choice

¹ Community Drug Distributors are community volunteers that were put forward by their communities to be trained to distribute antimalarial treatment for the prevention of malaria targeting children aged 3-59months.

104 of cycle 4, which is the last cycle of SMC, allows for the implementation of SMC-VAS integration without affecting
 105 the next SMC cycle within the year.

106 Eligible children aged six months to less than 12 months received SPAQ1 (Amodiaquine 76.5 mg +
 107 Sulphadoxine/Pyrimethamine 250/12.5 mg dispersible tablets) and 100,00 IU Vitamin A, while children who were
 108 12 months to less than 60 months received SPAQ2 (Amodiaquine 153 mg + Sulphadoxine/Pyrimethamine 500/25
 109 mg dispersible tablets) and 200,000 IU Vitamin A (Table 1 and 2). Children who were 3 – 6months received SPAQ
 110 only.

111 **Table 1: Eligibility criteria for SPAQ and Vitamin A administration**

Eligibility for SPAQ (SMC)	Eligibility for Vitamin A supplementation
Inclusion criterion	Inclusion criterion
Between 3-59 months	Between 6-59 months
Exclusion criteria	Exclusion criteria
Child is 5-10 years	Child is 5-10 years
Child is very sick	Child has severe respiratory infection or difficulty with breathing
Child has a fever	Taken vitamin A in the past month
Child allergy to SP or AQ or cotrimoxazole	Child allergic to vitamin A and/or any of its component ingredient
Child has taken SP or cotrimoxazole in the last 4 weeks	

112

113

114 **Table 2: Details of the drugs and supplements used during the campaigns.**

S/N	Generic Name	Age group
1	Amodiaquine 76.5 mg + Sulphadoxine/Pyrimethamine 250/12.5 mg dispersible tablets (SPAQ1)	Children 3 month to less than 12 months

2	Amodiaquine 153 mg + Sulphadoxine/Pyrimethamine 500/25 mg dispersible tablets (SPAQ2)	Children 12 months to 59 months
3	Vitamin A supplement (100,000IU)	Children 3 month to less than 12 months
4	Vitamin A supplement (200,000IU)	Children 12 months to 59 months

115

116 Training of CDDs and supervisors occurred before the onset of Cycle 1, and additional training was held in Cycle 4
117 for the integration of Vitamin A into the SPAQ campaign. For the SMC-VAS co-delivery, the CDDs followed the
118 standard operating procedure for SMC, with additional steps to guide them on how to determine eligibility, administer
119 Vitamin A to the 6 – 59-month age group, provide key messages on both interventions and referral of cases. CDDs
120 moved in teams of two persons, one providing treatment of SPAQ and vitamin A, and the other tallying and recording
121 treatments in four records: the SMC Tally Sheet, Growth Monitoring Register, Vitamins A sticker to affix to Child
122 Health Card, and Child SMC Card. CDDs teams were attached to health facilities for commodity logistics and
123 submission of reports. A designated health facility worker provided supportive supervision to the CDD teams
124 attached to the facility. State and LGA teams monitored activities at the facility and community levels using standard
125 checklists while the study teams also monitored the campaign for quality assurance. Ethical approval for the
126 implementation research was provided by the Bauchi State Ethics Committee under the Ministry of Health and
127 written informed consents were received from all participant, who also consented to their data being used for future
128 research so long as they are de-identified. The cost analysis utilized administrative and implementation cost data with
129 no identifiers.

130 **Costing**

131 An ingredient-based costing approach[15,16] using a mix of primary and secondary data was employed in this study,
132 and the data were collected between October and December 2021. Program data was obtained from the campaign
133 monitoring and evaluation records.

134 The methodological guidelines of Boonstoppel et al (2021) on how to cost immunization campaigns were
135 adopted[17]. An independent public health specialist with experience in economic evaluation led the development
136 of the cost analysis protocol, with input from various stakeholders following a series of virtual and physical meetings.
137 A one-day workshop to clarify the scope, methodology, as well as the data extraction plan for the study was held
138 with staff of Malaria Consortium Bauchi State field office (Monitoring and Evaluation Officer and Finance Officer),

139 the Malaria Consortium Country Officers (Public Health Specialist, Finance Officer, Monitoring and Evaluation
140 Officer, and other support staff), representatives from the Bauchi State Ministry of Health, and representative of
141 Vitamin Angels (a partner non-governmental organization, which donated all the Vitamin A distributed during the
142 study). This study team developed a costing template used to collect costs data from the state and country offices by
143 the finance officers at state and country level. Cost data and other relevant data were also extracted from the
144 programmatic, financial, and coverage data from monitoring and evaluation records. Program staff clarified the levels
145 of staff effort to estimate the economic value of human resources input in the study, as SMC–VAS integration was
146 an additional responsibility to their routine work. Microsoft Excel 2016 was used to aggregate all the extracted costs.

147 Data collection started in October 2021 after Cycle 1 had been completed, so only retrospective data were collected
148 for this cycle. Data for Cycle 4 was collected prospectively during the intervention period and retrospectively
149 afterwards to fill any missing gaps in the data collected. The time horizon for this study was one year, with 2021 as
150 the baseline. The costs were aggregated to enable comparison between SMC with and without VAS administration.
151 Due consideration was made for costs incurred by staff at the national malaria program and the Ministry of Health
152 levels, by the Malaria Consortium, and by donors to the SMC-VAS project. There was no direct cost to the
153 beneficiaries in this study, as Vitamin A and SPAQ were given at no tangible cost to the children during door-to-
154 door campaigns. Hence the cost analysis did not include that of the beneficiaries.

155 **Cost categories**

156 In this cost analysis, both economic and financial costs for delivery of the integrated services were assessed. Financial
157 costs are typically captured in project financial records while economic costs were estimated based on assumptions,
158 such as level of effort of human resources and market prices of relevant items[18]. We estimated economic costs in
159 this analysis as the value of all resources utilized, regardless of the source of financing. The economic costs estimated
160 also included the opportunity cost of labour as well as donations to the project (e.g., Vitamin A donated by Vitamin
161 Angels). It was particularly important to outline the opportunity cost of labour as the labour cost captured in the
162 financial records was for staff covering the 10 LGAs of the SMC campaign while this cost analysis covered only the
163 two LGAs where the SMC-VAS integration campaign was being carried out[15].

164 The cost data were initially captured as capital and operating costs and originating from the MC field office in Bauchi
165 State, and the MC country office. Operating costs are the costs of inputs used frequently and are used up in one year.
166 Also, for comparability with other studies, campaign specific costs were delineated from shared costs. Campaign
167 costs refer to those costs utilized solely for this integrated intervention, while shared costs are those costs that the
168 integrated intervention shared with other ongoing interventions' program activities. Training of CDDs and

169 supervisors occurred before the onset of Cycle 1, and additional training was held in Cycle 4 for the integration of
 170 Vitamin A into the SPAQ campaign.

171 Costs were fit into the following activity categories: distribution cost, drug cost (SPAQ and vitamin A separately),
 172 training, supplies, meetings, labor cost, supervision, and social mobilization. The subcategories under each of these
 173 cost categories (shown in Annex 1) were used in a cost-effectiveness study of a district-wide SMC intervention in
 174 Mali [16]. However, in this present study, the transportation cost/allowance was retained under the respective cost
 175 categories in which they occurred, as the drug distributors and supervisors were separately given transportation
 176 allowance. The cost of Vitamin A and SPAQ was estimated as the market price per dose of either drug (Table 3).
 177 Figure 2 (Materials used for Cycle 1 (SMC) and 4 (SMC-VAS) campaigns, in Giade and Katagum LGAs, Bauchi
 178 State 2021) below shows some of the materials used for the SMC-VAS campaign.

179 Table 31: Unit cost of SPAQ and Vitamin A used in the SMC-VAS integration intervention

Commodities	Unit price/capsule (USD) in MONTH YEAR
Vitamin A 100,000 IU	0.020
Vitamin A 200,000IU	0.022
SPAQ1	0.26
SPAQ2	0.29

180

181 Since the drug delivery in the integrated intervention was community based, the costs for actual delivery to the
 182 children were captured from the project financial records as the wages and benefits for the CDD and their supervisors,
 183 as well as other program related costs. No volunteer time was reported in this study. Costs not included in this analysis
 184 are:

- 185 1. Management costs of Malaria Consortium
- 186 2. Capital costs (vehicles, motorcycles, or health facilities)
- 187 3. Non-financial costs (e.g., volunteer time and recipient/family costs)
- 188 4. Coverage surveys and drug resistance monitoring

189 We excluded inventory and utility costs based on the recommendation from methodological guidance on costing
 190 immunization campaigns which assumes that the share of the building space allocated to a campaign of a limited
 191 number of days is small[15]. The cost is reported in Naira with conversion to USD at 2021-dollar value (NGN409.6

192 to USD1) based on the average (median) Naira-Dollar exchange for year 2021 as provided by the Central Bank of
193 Nigeria. The percentage share of associated cost categories of the total cost was also estimated.

194 Total cost was estimated first for SMC only and then SMC-VAS integrated intervention. The cost per child receiving
195 only SMC, and receiving both SMC and VAS were also estimated. This was straightforward in Cycle 1 as the children
196 only received SPAQ. In Cycle 4, consideration was made for both those children who received SMC alone and SMC-
197 VAS integration because the age range for SMC was broader than for VAS.

198 **Sensitivity analysis**

199 Univariate sensitivity analysis was conducted to evaluate how specific cost components affected the cost per child
200 receiving only SMC in the standalone SMC cycle, either SMC alone or both Vitamin A and SMC in the integration
201 cycle, and only SMC in the integration cycle. We examined four cost components: distribution, labor, SPAQ, and
202 supplies, and applied a 10% increase and decrease to each to allow for a robust assessment of how changes in these
203 cost factors might affect the overall cost of the intervention. For each scenario, we calculated the resultant 'cost per
204 child' and quantified its sensitivity by measuring deviations from the baseline. These deviations were then represented
205 visually using 'tornado plots'.

206 Research ethics approval for the study was received from the Bauchi State Ethics Review Committee and National
207 Health Research and Ethics Committee.

208 **Results**

209 The cost of delivering SMC as standalone and the cost of adding VAS to an existing SMC program. The total cost
210 for SMC only was \$158,934 while for SMC-VAS it was \$186,426 (Table 4). The largest driver of cost for both types
211 of campaigns was the cost of distribution accounting for 30.6% and 31.9% for SMC and SMC-VAS respectively.
212 This was followed by the cost of SPAQ, which accounted for 30.1% and 25.9% respectively. The proportion of the
213 cost of training was higher for SMC-VAS (24.4%) compared with SMC (18.1%). The cost of holding meetings
214 (which covers expenses such as venue costs, transportation allowances, lunch, accommodation, and per diem,
215 particularly for participants from out of station) was much higher for SMC-VAS at \$7,523 compared to SMC at
216 \$1,958. This cost difference of \$5565 accrued from additional meetings that needed to be held with stakeholders for
217 the introduction of Vitamin A into the SMC campaign cycle. The cost of supplies for SMC was significantly higher
218 at \$25,114 than for SMC-VAS at \$13,748. Similarly, supplies took a higher proportion of the cost for SMC (15.8%)

219 compared with SMC-VAS (7.4%). This was because many of the items procured at Cycle 1 were planned for the
 220 entire SMC round and items such as visibility materials and job aids were also reused in Cycle 4.

221 The cost of supervision and distribution was higher for SMC-VAS compared to SMC because distribution occurred
 222 for five days for SMC-VAS, and for four days for SMC. Overall, although the cost of the Vitamin A distributed was
 223 only \$3,440, integrating Vitamin A into Cycle 4 added \$27,492 over the cost of Cycle 1. Table 5 shows the breakdown
 224 of the main-cost categories by financial and opportunity cost categories.

225 Table 2: The main cost categories of cost analysis, and proportion of total cost, for the SMC campaign in Cycle 1
 226 (SMC) and 4 (SMC-VAS) campaigns, in Giade and Katagum LGAs, Bauchi State 2021

Cost category	SMC		SMC-VAS	
	Cost (\$)	Proportion	Cost (\$)	Proportion
Distribution cost	48,565.67	30.6	59,472.34	31.9
SPAQ	47,771.74	30.1	48,213.71	25.9
Training	28,783.33	18.1	45,544.69	24.4
Supplies	25,114.65	15.8	13,748.13	7.4
Meetings	1,958.13	1.2	7,523.41	4.0
Labour cost	6,301.28	4.8	6,746.47	3.6
Supervision	439.42	0.3	945.60	0.5
Vit A	-	-	3,416.90	1.8
Social mobilization	-	-	815.36	0.4
Total	158,934.21	100.0	186,426.60	100.0

227

228 Table 5: The main cost categories of cost analysis by financial and opportunity costs for the SMC campaign in Cycle
 229 1 (SMC) and 4 (SMC-VAS) campaigns, in Giade and Katagum LGAs, Bauchi State 2021

Cost Categories	SMC		SMC-VAS	
	Financial Cost (\$)	Opportunity cost (\$)	Financial Cost (\$)	Opportunity cost (\$)
Distribution cost	48,565.67		59,472.34	
SPAQ	47,771.74		48,213.71	
Supervision	439.42		945.60	
Supplies	25,114.65		13,748.13	
Training	28,783.33		45,544.69	

Meetings	1,765.88	192.24	7,523.41	
Social mobilization			815.36	
Labor cost		6,301.28		6,746.47
Vitamin A				3,416.90
Total	159,469.49	6,493.53	176,263.23	10,163.37

230

231 **Table 6** shows the coverage of SMC in Cycle 1 and SMC-VAS in Cycle 4. A total of 168,820 children under 5 years

232 received SPAQ1 and SPAQ2 in the two study LGA in Cycle 1 while it was 170,681 children in Cycle 4. Among the

233 children that received SPAQ1 or SPAQ2 in Cycle 4, 158,258 also received Vitamin A supplements during the

234 campaign.

235

236

237

238

239 Table 6: Coverage and quantity of drugs SPAQ and Vitamin A capsules used in Giade and Katagum LGAs, Bauchi

240 State in Cycle 1 and 4 of the SMC and SMC-VAS campaigns, 2021

Coverage category	Cycle 1			Cycle 4		
	3 to <12m	12 to <59m	Total	3 to <12m	12 to <59m	Total
SPAQ						
Number of children who received SPAQ	32769	136051	168820	33539	137142	170681
Number of blisters wasted*	157	301	458	58	143	201
Total Number of SPAQ capsules used	32926	136352	169278	33597	137285	170882
Vitamin A						
Number of children who received Vitamin A				20498	137378	157876
Number of capsules wasted*				99	243	342
Total Number of Vitamin A capsules used in cycle				20547	137711	158258

241 * Each blister/capsule represents a child's dose

242 Table 7 shows the cost per child receiving only SMC in the standalone SMC cycle, either SMC alone or both Vitamin

243 A and SMC in the integration cycle, and only SMC in the integration cycle. For children who received only SMC in

244 Cycle 1, we estimate the economic cost to be \$0.94 per child, while it cost \$1.18 per child to provide eligible children
 245 with combination of SPAQ and Vitamin A during an SMC cycle.

246 Table 7: Estimation of Cost per child receiving only SMC (Cycle 1), both Vitamin A and SMC, and only SMC (Cycle
 247 4), only both Vitamin A and SMC, or only SMC (Cycle 4) in the study LGAs

Cycle	Offered to Child	Cost Indicator: Total Cost...	Total Cost (\$)	No. of Children reached	Cost per Child (\$)
1	SMC alone	per child receiving only SMC	158,934.22	168820	0.94
2	SMC+VAS	per child receiving both Vitamin A and SMC	186,426.61	157876	1.18

248

249 In the sensitivity analyses (Annex 2), the 'SMC only' cycle showed a \$0.03 sensitivity on cost per child to changes in
 250 distribution costs. The other cycles, SMC±VAS and SMC+VAS, demonstrated a similar sensitivity of about \$0.04.
 251 In contrast, the 'Supplies' component had minimal impact on the 'cost per child' across all cycles, indicating its low
 252 sensitivity. The effects of 'Labour cost' and 'SPAQ cost' components varied, affecting the 'cost per child' by about
 253 \$0.01 to \$0.03. The implementers had adjusted the operational strategy by instituting a 30-minute wait between the
 254 administration of SMC medicines and VAS, and by revising the daily distribution targets from 70 to 56 children,
 255 with an added implementation day. These adjustments, aimed at maintaining the quality of the campaign without
 256 significantly elevating costs, are supported by the sensitivity analysis. This analysis validates the implementers'
 257 decisions, suggesting that the operational modifications aligned with the empirical cost sensitivities identified post-
 258 implementation.

259 **Discussions**

260 The findings from this study shed light on the intricacies of incorporating Vitamin A supplements into SMC
 261 campaigns, highlighting both the associated costs and the primary cost drivers. The analysis reveals that the cost to
 262 cover a child for one SMC cycle is less than \$1.00, suggesting that the expense for all four cycles would not exceed
 263 \$4.00 per child, as subsequent cycles do not incur the initial set-up costs. These estimates are consistent with previous
 264 research; for example, Baba et al. (2020) reported an estimated weighted average economic cost of administering
 265 four cycles at \$2.71 to \$8.20 per child across various African countries utilizing a door-to-door distribution strategy
 266 [15]. Conversely, a study in Ghana estimated a range from \$4.61 to \$26.14 per child, influenced by regional
 267 differences [19]. Moreover, a comprehensive delivery assessment in Senegal found economic costs per SMC course
 268 ranging from \$0.38 to \$2.74[5]. These comparative findings emphasize the importance of contextualized strategies

269 for implementing SMC programs and call for a more rigorous comparative analysis to account for differences in
270 methodology, regional economic conditions, and implementation scale. However, it is important to point out the
271 methodology for calculating costs differed among these studies.

272 Additionally, the study indicated that incorporating Vitamin A into a standard SMC cycle led to an incremental cost
273 of just \$0.24 per child covered for both SMC and VAS. When considering the broader scope of the campaign, which
274 encompasses all eligible children, the incremental cost further decreased to \$0.11 per child. This has profound
275 implications for the economic viability of adding Vitamin A supplementation to SMC programs. The nominal
276 additional cost implies that it could be an attractive policy for public health officials, offering a dual benefit of malaria
277 prevention and enhanced nutritional status for at-risk, underserved populations. Substantial benefits that may arise
278 from the modest additional per-child cost, including the potential to reduce both malaria morbidity and mortality and
279 to improve Vitamin A status. A study by Shankar et al. (1999) among children under five in Papua New Guinea
280 indicated that VAS is an economical approach to decrease morbidity caused by *P. falciparum*, with a 30% reduction
281 in illness episodes among supplemented children compared to those without supplements [20,21]. Thus,
282 incorporating Vitamin A into SMC, a low-tech yet effective intervention, appears to be a cost-effective strategy for
283 advancing child health.

284 Detailed examination of the integration costs reveals that, although initial expenses for training and material
285 procurement are one-off, other costs such as monitoring and supply chain management could recur with each cycle,
286 necessitating a nuanced understanding of this cost structure for sustained integration. The investment in training and
287 meetings necessary to integrate VAS into SMC represents a higher initial cost that should diminish over time once
288 the integration process becomes routine. These upfront investments in capacity building are expected to result in
289 long-term enhancements in both the efficiency and efficacy of the program. As the teams involved gain proficiency
290 in delivering combined services, the resources needed for subsequent initial and refresher trainings and meetings are
291 projected to decrease, potentially lowering the overall cost per child in future cycles and bolstering the sustainability
292 of the integrated approach. This anticipated decrease in training and meeting costs aligns with the need for accurate
293 data and distribution cost estimates, as highlighted by the sensitivity analysis which underscores the 'distribution'
294 component as a critical cost driver.

295 Similarly, materials acquired for the SMC campaign, such as educational resources, medication packages, and health
296 worker protective equipment, can be used throughout the four SMC cycles. Given that VAS is integrated into only
297 one of the four SMC cycles annually, the costs for these materials can be classified as initial expenditures. This study
298 accounted for these costs only in the context of the standalone SMC to reflect the integration pattern within the four-

299 cycle SMC framework. Spreading these costs over multiple cycles could further highlight the cost-effectiveness of
300 the integrated model.

301 **Study Limitations**

302 This study's cost analysis, limited to two cycles, one with Vitamin A integration and one without, does not provide a
303 comprehensive estimate of the cost per child over the full four cycles of SMC or for exclusive Vitamin A
304 supplementation (VAS). Also, the timing of integration—whether during the 4th cycle with VAS/SMC or the 1st
305 cycle, when engagement in SMC is potentially higher—may influence outcomes. Moreover, the analysis does not
306 account for the expenses incurred by the beneficiaries' parents or guardians participating in the stand-alone or
307 integrated campaign. This gap is due to the door-to-door drug delivery strategy employed in this study, which
308 excludes the opportunity cost related to the time spent by parents or guardians with the drug distributors. Additionally,
309 incorporating administrative costs beyond the country office of the implementing organization (i.e., Malaria
310 Consortium) in the costs would notably increase the total campaign cost. Nevertheless, this study conformed to
311 established costing guidelines for such campaigns by excluding these above-country overhead costs, thereby ensuring
312 that its findings remain consistent and relevant to similar public health initiatives[15]. While some elements of the
313 cost analysis, like 'supplies,' confirm the soundness of our methodology, as its variations minimally impact the overall
314 result, others, specifically 'distribution,' indicate areas of potential risk to the success of integration programs.
315 Nonetheless, it is crucial to note the study was a cost analysis that did not assess the cost-effectiveness in achieving
316 specific health outcomes, including decreased under-5 mortality, lower malaria incidence among under-5s, and
317 reductions in malnutrition rates.

318 In this study, cost analyses were performed for children receiving only Seasonal Malaria Chemoprevention (SMC)
319 and those receiving both SMC and Vitamin A Supplementation (VAS). The distinction was straightforward in first
320 cycle, where only SPAQ was administered. In contrast, Cycle 4 required nuanced consideration of two distinct
321 categories—children receiving only SMC and those part of the integrated SMC-VAS program—attributable to the
322 broader age range eligible for SMC compared to VAS. While this approach is critical to ensure that interventions are
323 comprehensive and meet the varied needs of the target population, future studies may refine their assessment of the
324 integration strategy to focus exclusively on the age groups eligible for each specific intervention. Finally, the
325 applicability of this analysis across different Nigerian settings may be limited due to variability in supply and
326 distribution costs.

327 **Conclusion**

328 The cost per child for an SMC standalone campaign and an SMC-VAS integrated campaign was estimated using an
329 ingredient-costing methodology. This analysis of both financial and economic costs provides insights into the
330 feasibility of integrating Vitamin A distribution into the standard SMC cycle, revealing an additional cost of \$0.24
331 per child. This incremental cost is relatively minimal, suggesting that the integration of Vitamin A delivery into an
332 SMC cycle is a worthwhile investment, especially considering the health benefits for children under five years of
333 age. Although scaling up a routine SMC-VAS program is advisable, future research should focus on conducting a
334 cost-effectiveness analysis of their integration, incorporating population-based coverage surveys and reported rates
335 of malaria, nutritional deficiencies, and overall child morbidity and mortality.

336 **Acknowledgement**

337 The authors acknowledge Dr. Perpetua Uhomoibhi, the former National Coordinator, NMEP and
338 Dr. Nnenna Ogbulafor, the Head of Case management branch, NMEP, for their support in
339 stakeholder engagement. We appreciate all members of the Malaria Consortium country office
340 Finance staff, Bauchi state project team, the Executive Chairman, Bauchi State Agency for the
341 Control of AIDS, Tuberculosis and Malaria, the Executive Secretary, Bauchi state Primary Health
342 Care Board; the state Malaria Program Manager, Alhaji Babuga, and all others not mentioned
343 but supported the data collection and validation process. We express our appreciation to the
344 community drug distributors and health facility workers, who support SMC delivery to eligible
345 children in communities and participated in this study.

346

347 **References**

- 348 1. World Health Organization. Children: improving survival and well-being [Internet]. 2020 [cited 2024 Jan 8].
349 Available from: <https://www.who.int/news-room/fact-sheets/detail/children-reducing-mortality>
- 350 2. UNICEF. Under-five mortality [Internet]. UNICEF DATA. 2023 [cited 2024 Jan 8]. Available from:
351 <https://data.unicef.org/topic/child-survival/under-five-mortality/>

- 352 3. Brown ME, Backer D, Billing T, White P, Grace K, Doocy S, et al. Empirical studies of factors associated with
353 child malnutrition: highlighting the evidence about climate and conflict shocks. *Food Secur.* 2020;12:1241–52.
- 354 4. Tam E, Keats EC, Rind F, Das JK, Bhutta ZA. Micronutrient Supplementation and Fortification Interventions on
355 Health and Development Outcomes among Children Under-Five in Low- and Middle-Income Countries: A
356 Systematic Review and Meta-Analysis. *Nutrients.* 2020;12:289.
- 357 5. Mayo-Wilson E, Imdad A, Herzer K, Yakoob MY, Bhutta ZA. Vitamin A supplements for preventing mortality,
358 illness, and blindness in children aged under 5: systematic review and meta-analysis. *The BMJ.* 2011;343:d5094.
- 359 6. Kannan A, Tsoi D, Xie Y, Horst C, Collins J, Flaxman A. Cost-effectiveness of Vitamin A supplementation among
360 children in three sub-Saharan African countries: An individual-based simulation model using estimates from
361 Global Burden of Disease 2019. *PLOS ONE.* 2022;17:e0266495.
- 362 7. Aguayo VM, Baker SK. Vitamin A deficiency and child survival in sub-Saharan Africa: a reappraisal of challenges
363 and opportunities. *Food Nutr Bull.* 2005;26:348–55.
- 364 8. Aghaji AE, Duke R, Aghaji UCW. Inequitable coverage of vitamin A supplementation in Nigeria and implications
365 for childhood blindness. *BMC Public Health.* 2019;19:282.
- 366 9. Zegeye B, Olorunsaiye CZ, Ahinkorah BO, Ameyaw EK, Seidu A-A, Budu E, et al. Trends in inequality in the
367 coverage of vitamin A supplementation among children 6–59 months of age over two decades in Ethiopia:
368 Evidence from demographic and health surveys. *SAGE Open Med.* 2022;10:20503121221094688.
- 369 10. Ouédraogo O, Zeba AN, Kaboré S, Berthé A, Drabo KM, Ouaro Dabiré DB, et al. Acceptance and challenges of
370 the introduction of the routine community-based vitamin A supplementation strategy: the case of Burkina Faso.
371 *Public Health Nutr.* 2022;1–10.
- 372 11. Roschnik N, Diarra H, Dicko Y, Diarra S, Stanley I, Moestue H, et al. Adherence and acceptability of
373 community-based distribution of micronutrient powders in Southern Mali. *Matern Child Nutr.* 2019;15:e12831.
- 374 12. Oresanya O, Phillips A, Okereke E, Ahmadu A, Ibinaiye T, Marasciulo M, et al. Co-implementing vitamin A
375 supplementation with seasonal malaria chemoprevention in Sokoto State, Nigeria: a feasibility and acceptability
376 study. *BMC Health Serv Res.* 2022;22:871.

- 377 13. Yelwa A, Kerre F, Owino G. A Framework for the Identification of Triggers of Ethno-Religious Conflict in
378 Bauchi State, Nigeria. *Gusau Journal of Sociology* 2021. 2:42–55.
- 379 14. National Bureau of Statistic. National Nutrition and Health Survey(NNHS) 2018 [Internet]. 2018 [cited 2023
380 May 22]. Available from: https://nigerianstat.gov.ng/pdfuploads/NNHS_2018_Final%20Report.pdf
- 381 15. Baba E, Hamade P, Kivumbi H, Marasciulo M, Maxwell K, Moroso D, et al. Effectiveness of seasonal malaria
382 chemoprevention at scale in west and central Africa: an observational study. *The Lancet*. 2020;396:1829–40.
- 383 16. Diawara H, Walker P, Cairns M, Steinhardt LC, Diawara F, Kamate B, et al. Cost-effectiveness of district-wide
384 seasonal malaria chemoprevention when implemented through routine malaria control programme in Kita, Mali
385 using fixed point distribution. *Malar J*. 2021;20:128.
- 386 17. Boonstoppel L, Banks C, Moi F, Vaughan K, Ozaltin A, Brenzel L. How to Conduct an Immunization Campaign
387 Costing Study: Methodological Guidance. Wash DC ThinkWell. 2021;
- 388 18. Nonvignon J, Aryeetey GC, Issah S, Ansah P, Malm KL, Ofori W, et al. Cost-effectiveness of seasonal malaria
389 chemoprevention in upper west region of Ghana. *Malar J*. 2016;15:367.
- 390 19. Hollm-Delgado M-G, Piel FB, Weiss DJ, Howes RE, Stuart EA, Hay SI, et al. Vitamin A supplements, routine
391 immunization, and the subsequent risk of Plasmodium infection among children under 5 years in sub-Saharan
392 Africa. *eLife*. 4:e03925.
- 393 20. Shankar AH, Genton B, Semba RD, Baisor M, Paino J, Tamja S, et al. Effect of vitamin A supplementation on
394 morbidity due to Plasmodium falciparum in young children in Papua New Guinea: a randomised trial. *The Lancet*.
395 1999;354:203–9.
- 396 21. Pitt C, Ndiaye M, Conteh L, Sy O, Hadj Ba E, Cissé B, et al. Large-scale delivery of seasonal malaria
397 chemoprevention to children under 10 in Senegal: an economic analysis. *Health Policy Plan*. 2017;32:1256–66.

398 **Supporting information**

399 There are three supporting information file attached:

- 400 1. S1 Data set and cost categories
- 401 2. S2 Annex 1: Main cost categories and associated cost subcategories
- 402 3. S3 Annex 2: Sensitivity analyses




Figure 1: Typical design of SMC drug distribution campaign

Materials for SMC	Materials for VAS
<ul style="list-style-type: none"> ▪ SPAQ blister packs for infant dose - enough for all children 3-11 months of age ▪ SPAQ blister packs for child dose - enough for all children 12-59 months of age ▪ Clean spoon and cup ▪ Clean water ▪ SMC Record Card - to give to caregiver if the child has not been issued one in previous cycles 	<ul style="list-style-type: none"> ▪ Vitamin A 100,000 IU capsules - enough for all children 6-11 months of age ▪ Vitamin A 200,000 IU capsules - enough for all children 12-59 months of age ▪ Scissors - to cut off the narrow tip of the vitamin A capsule ▪ Plastic Bag and bin- to collect and dispose of used capsules ▪ Vitamin A stickers - to record VAS and place on Child Health Card ▪ Growth Monitoring Register – to record details of children given VAS
<ul style="list-style-type: none"> ▪ Hand hygiene materials - alcohol-based hand sanitizer or soap and clean water, clean towels ▪ SMC+VAS Job Aid - to follow steps for administration of SPAQ and vitamin A ▪ SMC+VAS Tally Sheet - to record the number of age appropriate doses distributed and the number of children reached with SPAQ and vitamin A ▪ Referral Form - for children or who with danger signs, have fever, or who have severe respiratory illness or have difficulty breathing ▪ Pens - for recordkeeping purposes ▪ Chalk – for marking houses ▪ Map - for daily activity 	

Figure 2: Materials used for Cycle 1 (SMC) and 4 (SMC-VAS) camp